A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodies

• Main Authors: Ruijun Zhang (Author), Ponraj Prabakaran (Author), Xiaocong Yu (Author), Brian C. Mackness (Author), Ekaterina Boudanova (Author), Joern Hopke (Author), Jose Sancho (Author), Jacqueline Saleh (Author), HyunSuk Cho (Author), Ningning Zhang (Author), Helene Simonds-Mannes (Author), Samuel D. Stimple (Author), Dietmar Hoffmann (Author), Anna Park (Author), Partha S. Chowdhury (Author), Sambasiva P. Rao (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hybridoma technology has been valuable in the development of therapeutic antibodies. More recently, antigen-specific B-cell selection and display technologies are also gaining importance. A major limitation of these approaches used for antibody discovery is the extensive process of cloning and expre...